Hepatitis c virus inhibitors

A compound represented by Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A and ring B are each independently optionally substituted phenyl or optionally substituted 6-membered heteroaryl containing one or more nitrogen atoms;
• Ring G and ring W are each independently optionally substituted 5-membered heteroaryl containing one or more nitrogen atoms;
• L1 is independently selected from the group consisting of —C(O)—R1, —C(O)—OR1, —OC(O)—R1, —C(O)—N(R1)2, —NR1C(O)—OR1, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, 3- to 7-membered heterocyclic and 5- to 7-membered heteroaryl, each optionally substituted;
• L2 is independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, O(C1-C4 alkyl), S(C1-C4 alkyl) and amino optionally substituted with one or two C1-C4 alkyl;
• Alternatively L1 and L2 are taken together with the carbon atom to which they are attached to form a spiro 3- to 7-membered ring selected from the group consisting of optionally substituted 3- to 7-membered heterocyclic, optionally substituted C3-C7 cycloalkenyl, and substituted C3-C7 cycloalkyl, wherein said C3-C7 cycloalkyl is substituted with at least one substituent other than C1-C6 alkyl;
• Y at each occurrence is independently C(O) or S(O)2;
• R1 at each occurrence is hydrogen or optionally substituted C1-C4 alkyl;
• R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted C3-C8 cycloalkyl;
• alternatively, R3 and R4 can be taken together with the carbon atom to which they are attached to form optionally substituted C3-C8 cycloalkyl or optionally substituted heterocyclic;
• R5 is hydrogen, optionally substituted C1-C8 alkyl, or optionally substituted C3-C8 cycloalkyl;
• Alternatively R3, R4 and R5 are taken together with the carbon atom and nitrogen atom to which they are attached to form
• U is absent or independently selected from O, S, S(O), SO2, NC(O)—(C1-C4 alkyl), C(O), protected carbonyl, OCH2, OCH2CH2, SCH2, SCH2CH2, C(R7)2, and C(R7)2C(R7)2;
• R7 at each occurrence is independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, O(C1-C4 alkyl), S(C1-C4 alkyl), amino optionally substituted with one or two C1-C4 alkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted C1-C4 alkyl;
• Alternatively two geminal R7 groups are taken together with the carbon atom to which they are attached to form a spiro, optionally substituted 3- to 7-membered ring selected from the group consisting of C3-C7 cycloalkyl, C3-C7 cycloalkenyl and 3- to 7-membered heterocyclic, each optionally substituted;
• R7a and R7b at each occurrence are each independently selected from the group consisting of hydrogen, optionally substituted aryl, and optionally substituted C1-C4 alkyl;
• Alternatively, CHR7a—U or CHR7b—U are taken together to form a group selected from CH═CH, fused and optionally substituted C3-C8 cycloalkyl, fused and optionally substituted aryl, or fused and optionally substituted heterocyclic;
• Yet alternatively, U, R7a, and R7b are taken together with the carbon atoms to which they are attached to form a bridged, optionally substituted 4- to 7-membered ring selected from the group consisting of C4-C7 cycloalkyl, C4-C7 cycloalkenyl and 4- to 7-membered heterocyclic, each optionally substituted;
• and
• R6 at each occurrence is independently selected from the group consisting of O(C1-C8 alkyl), amino, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, heterocyclic, aryl, and heteroaryl, each optionally substituted.